Immunotherapy for Cancer Treatment: 102 (AMW) Session
2021 AAO-HNSF Annual Meeting & OTO Experience
This is the second part of the popular course, Immunotherapy for Cancer: What the Otolaryngologist needs to Know. In recent years immunotherapy has shown promise as a new therapeutic pathway for the treatment of head and neck cancer. The second part of this course will focus on emerging biomarkers in oncology, ongoing clinical trials, and exciting future directions for the field. Understanding the current state and future directions of immunotherapy is valuable for counseling patients. This panel, geared toward general otolaryngologist, head and neck surgeons and trainees, will provide an in-depth review of biomarkers, ongoing clinical trials, and potential future agents.
Description
Learning Objective: 1. Understanding of new and emerging biomarkers for HNC. 2. Understanding of ongoing clinical trials evaluating immunotherapies for treatment of HNC. 3. Understanding of new and emerging immunotherapies for HNC. Faculty: Ravindra Uppaluri (Consulting Fee: Merck; Research Funding: NIH/NIDCR/NCI, Merck, V Foundation), Larissa Sweeny, MD(Nothing to Disclose), Nicole Schmitt, MD(Honoraria: Checkpoint Surgical; Research Funding: Astex Pharmaceuticals; Royalty: Plural Publishing), Daniel Faden, MD(Nothing to Disclose).